Skip to main content
. 2022 Aug 31;28(21):4642–4648. doi: 10.1158/1078-0432.CCR-22-1528

Table 2.

Confirmed best overall response rates according to RECIST v1.1 (FAS).

Atezolizumab + bevacizumab
N = 40
Best overall response, n (%)
 CR 1 (2.5)
 PR 17 (42.5)
 SD 8 (20.0)
 PD 13 (32.5)
 Not evaluable 1 (2.5)
ORR (CR+PR), n (%) 18 (45.0)
(95% Cl) (29.3–61.5)
Disease control rate (CR+PR+SD), n (%) 26 (65.0)
(95% Cl) (48.3–79.4)
DOR, months (95% Cl) 12.5 (5.5–NR)

Abbreviations: PD, progressive disease; SD, stable disease.